Hepatic artery infusion therapy for liver metastases after pancreatic/duodenal cancer surgery
Official title: Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma: A Prospective Feasibility Study
Run by AdventHealth · NCT07845617 · Data updated 2026-11-12
This study tests whether delivering chemotherapy directly to the liver via a pump can help people with pancreatic or duodenal cancer that has spread mainly to the liver after surgery and prior chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | AdventHealth Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Orlando, Florida) |
| Status | Recruiting |
| Started | November 1, 2026 |
| Main results expected | May 1, 2028 |
| Study ends | May 2, 2028 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT07845617 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-80 with histologically confirmed pancreatic or duodenal adenocarcinoma and isolated or liver-dominant metastases who are eligible for HAIP placement and FUDR-based chemotherapy.
✕Probably not a fit
Patients without liver-dominant disease, those not eligible for HAIP placement, or those with contraindications to FUDR may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center observational feasibility study at AdventHealth Orlando. It enrolls about 10 adults with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant metastases after primary treatment and systemic therapy. Participants receive a hepatic artery infusion pump with floxuridine-based chemotherapy and have data collected on liver tumor response, survival outcomes, and biomarkers. The primary focus is liver-specific response by RECIST 1.1, with secondary aims including progression-free and overall survival and changes in ctDNA, CEA, and CA 19-9, along with treatment-related safety data.
Why it matters
Potential benefit: If successful, this approach could improve liver tumor control and extend survival for patients with liver-dominant metastases from pancreatic or duodenal cancers.
How similar studies have gone: Previous regional hepatic therapies show promise in liver-dominant cancers, but evidence for HAIP with FUDR in pancreatic/duodenal cancers remains limited and this study is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-80 years * Histologically confirmed pancreatic or duodenal adenocarcinoma * Completed or currently receiving curative-intent treatment * Evidence of isolated or liver-dominant metastases (radiographic or clinical) * Deemed clinically eligible for hepatic artery infusion pump (HAIP) placement and floxuridine (FUDR)-based chemotherapy by a multidisciplinary oncology team * Scheduled for HAIP placement at AdventHealth Orlando Exclusion Criteria: \- Patients who are clinically ineligible for HAIP placement or FUDR therapy are excluded
Where it's running
-
AdventHealth Orlando
Orlando, Florida, United States Recruiting
Study contacts
- Study coordinator: Maggie Polanco, RN
- Email: maggie.polanco@adventhealth.com
- Phone: 407-303-7381
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Planned surgery or focused local treatment after chemo for metastatic upper-GI adenocarcinoma with undetectable ctDNA
This test sees if adding planned surgery or local treatments after three months of chemotherapy helps people with metastatic upper-gastrointestinal adenocarcinomas who have undetectable ctDNA.
-
Modified single-incision plus one-port laparoscopic pancreatoduodenectomy vs conventional five-port laparoscopic pancreatoduodenectomy for non-pancreatic periampullary cancers
This trial tests whether a less invasive single-incision plus one-port approach can match the safety and effectiveness of the standard five-port surgery in adults with non-pancreatic periampullary cancers requiring pancreaticoduodenectomy.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
THE-0504 in patients with solid tumors
A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.
-
Laparoscopic versus open pancreaticoduodenectomy outcomes
This trial will test whether laparoscopic (keyhole) pancreaticoduodenectomy leads to fewer complications and faster recovery than open pancreaticoduodenectomy in adults with resectable pancreatic or periampullary tumors.
-
Preventing complications after high-risk Whipple (pancreatoduodenectomy) with hydrocortisone, octreotide, and a teres ligament patch
This tests whether giving hydrocortisone and octreotide around surgery plus placing a teres ligament patch can lower major complications after Whipple surgery in patients with a small pancreatic duct.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.